Clinical Trial Update: Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis [Phase 1, Phase 2]

View source ↗

Summary

An update on safety for intraperitoneal oxaliplatin with systemic FOLFIRI plus bevacizumab in peritoneal carcinomatosis, spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peritoneal Carcinomatosis

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Peritoneal Carcinosis | Phase 1, Phase 2 | Status: UNKNOWN